Pharmaceutical Technology: "Roundtable: Experts Share Their Views on Clinical Trial Transparency"

Pharmaceutical Technology recently interviewed our Chief Development Officer, Tom Krohn, about the current state of transparency in clinical trials and where to go from here. 

"A study published by The BMJ in 2012 found that only 22% of clinical trial data covered by the FDAA is submitted within one year of completion. The opacity of clinical trial data means that the medical community often lacks access to a complete picture of a drug or device’s efficacy, safety and side-effects. In recent years, efforts have been made to ensure results from current trials are registered and reported, and non-compliance is enforced. But is enough being done to ensure data is accessible, complete and ultimately of use to researchers, physicians and patients?..."